91大香蕉

91大香蕉
91大香蕉 91大香蕉
GettyImages-609179959-hero
Hematology and Oncology

Dong Molecular Epidemiology Laboratory

Research undertaken by the Dong Lab is focused on integrating cutting-edge omics technology into large epidemiologic cohorts to build a multidisciplinary research program for developing approaches to reduce cancer burden and cancer disparities. Specifically, we use genome-wide association study (GWAS) and next-generation sequencing (NGS) techniques, as well as large administrative database such as the Surveillance, Epidemiology, and End Results (SEER) program and TriNetX, to identify genetic and non-genetic factors that are associated with cancer development, progression, and cancer disparities. We also leverage these risk factors to develop polygenic risk score and risk prediction models for cancer.

About the PI

Jing Dong, PhDJing Dong, PhD, Assistant Professor, received her PhD in Epidemiology at Nanjing Medical University, China in 2012. During her PhD training under the supervision of Dr. Hongbing Shen, she focused on identifying potential functional/tagging single nucleotide polymorphisms (SNPs) that are associated with cancer susceptibility and prognosis. She participated in a multicenter GWAS of lung cancer in the Han Chinese population and identified five novel susceptibility loci for lung cancer and one locus specifically for lung squamous cell carcinoma in Chinese populations. After completing her doctoral degree, Dr. Dong joined the laboratory of Drs. Honglei Chen and Stephanie London at NIEHS/NIH as a visiting fellow to expand her training in large cohort-based epidemiological study. In 2017, she was awarded by Cancer Prevention and Research Institute of Texas (CPRIT) to join a training program in Integrative Cancer Epidemiology at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine (Margaret Spitz, PI). She worked with Dr. Aaron Thrift to investigate risk factors of Barrett’s esophagus and esophageal adenocarcinoma and developed the first polygenic risk score and risk prediction models for these two diseases. Under the guidance of Dr. Lee-Jun Wong, she also established a pipeline in applying NGS to decipher the mitochondrial genomic landscape in cancer for population-based studies.

In 2020, Dr. Dong joined the Division of Hematology and Oncology, Department of Medicine, 91大香蕉. She is also a member of the Cancer Center and the Mellowes Center for Genomic Sciences and Precision Medicine.

Current Research

Prognostic implications of mitochondrial inheritance in myelodysplastic syndromes after stem-cell transplantation.
This project is funded by the NHLBI (1K01HL164972-01A1). The goal is to identify mitochondrial genetic and epigenetic alterations associated with inferior outcomes in MDS patients after allogeneic HCT. This study will be the first to use cutting-edge NGS technology to decipher the connections between mtDNA alterations and posttransplant outcomes in MDS. We hope to improve the identification of patients most likely to benefit from allo-HCT and spare those at high risk of inferior allo-HCT outcomes unnecessary transplant-related morbidity and mortality.

Genome-wide scan for susceptibility loci of multiple myeloma and it鈥檚 precursors
This project was funded by the Advancing a Healthier Wisconsin. The goal is to identify additional genetic susceptibility loci for patients with multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance (MGUS).

Genomic landscape and evolutional trajectory of multiple myeloma and its precursors in African Americans.
This project was funded by the MCW-Cancer Center/Mellowes Center. The goal is to characterize the somatic landscape of nuclear and mitochondrial genomes in multiple myeloma and its precursors in African Americans and identify genomic determinants of progression to myeloma and describe their temporal activities. These findings will improve our understanding of disease etiology and offer premalignant patients at “high-risk” of progression appropriate follow-up and early intervention, thereby avoiding the burden of incurable disease.

Landscape of pathogenic germline variants in multiple myeloma and its precursor in African Americans.
This project was funded by the American Cancer Society-Institutional Research Grant. The goal is to characterize the germline landscape of nuclear and mitochondrial genomes in multiple myeloma and its precursor monoclonal gammopathy of undetermined significance (MGUS) in African Americans and identify pathogenic germline variants for MGUS progression to MM.

Join Our Lab

Please contact us if you are a medical student, resident, fellow, faculty, post-doctoral associate, or graduate student interested in pursuing further training or research in molecular epidemiology.
Contact Jing Dong, PhD

Current Members

headshot

Shahram Arsang, PhD

Postdoctoral Fellow

headshot

Benjamin Massat, DO

Research Assistant

headshot

Gokul Pareek, BS

Research Assistant

Recent Publications

  • (Auer PL, Farazi M, Zhang T, Dong J, Bolon YT, Spellman SR, Saber W.) Am J Hematol. 2024 Apr;99(4):770-773 PMID: 38339773 PMCID: PMC10947828 SCOPUS ID: 2-s2.0-85184938817 02/10/2024

  • (Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C.) Blood Cancer J. 2024 Mar 06;14(1):38 PMID: 38443358 PMCID: PMC10915134 SCOPUS ID: 2-s2.0-85186929795 03/06/2024

  • (Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B.) Br J Haematol. 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023

  • (Buradagunta CS, Arsang-Jang S, Massat B, Thapa B, Patek V, D'Souza A, Auer P, Urrutia R, Janz S, Dhakal B, Hari P, Dong J.) Leukemia. 2024 Feb;38(2):383-385 PMID: 37919604 PMCID: PMC11326531 SCOPUS ID: 2-s2.0-85175540732 11/03/2023

  • (Guru Murthy GS, Zhang T, Bolon YT, Spellman S, Dong J, Auer P, Saber W.) Biomark Res. 2024 Jan 25;12(1):10 PMID: 38273355 PMCID: PMC10809608 01/26/2024

  • (Guru Murthy GS, Zhang T, Bolon YT, Spellman S, Dong J, Auer P, Saber W.) Biomarker Research. December 2024;12(1) SCOPUS ID: 2-s2.0-85182980987 12/01/2024

  • (Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A.) Bone Marrow Transplant. 2023 Aug;58(8):953-955 PMID: 37149674 PMCID: PMC10555486 SCOPUS ID: 2-s2.0-85158126520 05/07/2023

  • (Zhang T, Auer P, Dong J, Cutler C, Dezern AE, Gadalla SM, Deeg HJ, Nazha A, Carlson KS, Spellman S, Bolon YT, Saber W.) J Hematol Oncol. 2023 Apr 11;16(1):37 PMID: 37041565 PMCID: PMC10088148 SCOPUS ID: 2-s2.0-85152260295 04/12/2023

  • (Dong J, Buradagunta CS, Zhang T, Spellman S, Bolon YT, DeZern AE, Gadalla SM, Deeg HJ, Nazha A, Cutler C, Cheng C, Urrutia R, Auer P, Saber W.) J Hematol Oncol. 2023 Mar 10;16(1):21 PMID: 36899395 PMCID: PMC9999628 SCOPUS ID: 2-s2.0-85149930611 03/11/2023

  • (D'Souza A, Brazauskas R, Teng BQ, Yun G, Uttley H, Dong J, Dwinell MB, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Janz S.) Bone Marrow Transplant. 2023 Mar;58(3):334-336 PMID: 36460820 SCOPUS ID: 2-s2.0-85143207078 12/03/2022

  • (Dong J, Li J, Buradagunta CS, Janz S, Urrutia R, Cheng C.) Blood 2022; 140 (Supplement 1): 10054鈥�10055.. 11/15/2022

  • (Massat B, Pareek G, Buradagunta CS, Thapa B, Auer P, Dhakal B, Janz S, Hari P, Dong J.) Blood 2022; 140 (Supplement 1): 10063鈥�10064.. 11/15/2022

Publications of from the